U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07669194) titled 'Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma' on June 22.
Brief Summary: Assess the efficacy and safety of glofitamab in combination with selinexor for the treatment of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) in patients who have received at least two prior lines of systemic therapy.
Study Start Date: June 10
Study Type: OBSERVATIONAL
Condition:
Diffuse Large B-Cell Lymphoma (DLBCL)
Intervention:
DRUG: Glofitamab combined with selinexor
Patients receive obinutuzumab 1000 mg intravenously (IV) on Day 1 of Cycle 1 to mitigate cytokine release synd...